Review of clinical trials conducted in Waldenstrom macroglobulinemia and recommendations for reporting clinical trial responses in these patients

References

• Dimopoulos MA, Alexanian R. Waldenstrom's macroglobulinemia. Blood 1994;83:1452–1459.
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Gertz MA, Fonseca R. Waldenstrom macroglobulinaemia. Lancet Oncol 2003;4:679–685.
   PubMed Web of Science ®Google Scholar
• Vijay A, Gertz MA. Waldenstrom macroglobulinemia. Blood 2007;109:5096–5103.
   PubMed Web of Science ®Google Scholar
• Treon SP. How I treat Waldenstrom's macroglobulinemia. Blood 2009;114:2375–2385.
   PubMed Web of Science ®Google Scholar
• Waldenstrom J. Incipient myelomatosis or ‘essential’ hyperglobulinemia with fibrinogenopenia—a new syndrome? Acta Med Scand 1944;117:216–247.
   Google Scholar
• Treon SP, Dimopoulos M, Kyle RA. Defining Waldenstrom's macroglobulinemia. Semin Oncol 2003;30:107–109.
   PubMed Web of Science ®Google Scholar
• Jemal A, Murray T, Ward E, et al Cancer statistics, 2005. CA Cancer J Clin 2005;55:10–30.
   PubMed Web of Science ®Google Scholar
• Herrinton L, Weiss NS. Incidence of Waldenstrom's macroglobulinemia. Blood 1993;82:3148–3150.
   PubMed Web of Science ®Google Scholar
• Owen RG, Treon SP, Al-Katib A, et al Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003;30:110–115.
   PubMed Web of Science ®Google Scholar
• Remstein ED, Hanson CA, Kyle RA, Hodnefield JM, Kurtin PJ. Despite apparent morphologic and immunophenotypic heterogeneity, Waldenstrom's macroglobulinemia is consistently composed of cells along a morphologic continuum of small lymphocytes, plasmacytoid lymphocytes, and plasma cells. Semin Oncol 2003;30:182–186.
   PubMed Web of Science ®Google Scholar
• Hunter Z, Branagan AR, Manning R, et al CD5, CD10, and CD23 expression in Waldenstrom's macroglobulinemia. Clin Lymphoma 2005;5:246–249.
   PubMedGoogle Scholar
• Dimopoulos MA, Kyle RA, Anagnostopoulos A, Treon SP. Diagnosis and management of Waldenstrom's macroglobulinemia. J Clin Oncol 2005;23:1564–1577.
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Fonseca R, Gertz MA, et al Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia. Br J Haematol 2006;133:158–164.
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Witzig TE. Waldenstrom macroglobulinemia. Curr Treat Options Oncol 2004;5:239–247.
   PubMedGoogle Scholar
• Vijay A, Gertz MA. Current treatment options for Waldenstrom macroglobulinemia. Clin Lymphoma Myeloma 2008;8:219–229.
   PubMedGoogle Scholar
• Schnitzler L, Schubert B, Boasson M, Gardais J, Tourmen A. Urticaire chronique, lésions osseuses, macroglobulinémie IgM: maladie de Waldenstrom? Bull Soc Fr Derm Syph 1974;81:363–367.
   Google Scholar
• Gertz M, Kyle RA, Noel P. Primary systemic amyloidosis: a rare complication of immunoglobulin M monoclonal gammopathies and Waldenstrom's macroglobulinemia. 1993;11:914–920.
   Google Scholar
• Morel P, Duhamel A, Gobbi P, et al International prognostic scoring system for Waldenstrom's macroglobulinemia. Blood 2009;113:4163–4170.
   PubMed Web of Science ®Google Scholar
• Treon SP, Gertz MA, Dimopoulos M, et al Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia. Blood 2006;107:3442–3446.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Treon SP, Alexanian R, et al Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003;30:116–120.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Gertz MA, Kastritis E, et al Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia. J Clin Oncol 2008;27:120–126.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Greipp PR, Gertz MA, et al Waldenstrom's macroglobulinaemia: a prospective study comparing daily with intermittent oral chlorambucil. Br J Haematol 2000;108:737–742.
   PubMed Web of Science ®Google Scholar
• Facon T, Brouillard M, Duhamel A, et al Prognostic factors in Waldenstrom's macroglobulinemia: a report of 167 cases. J Clin Oncol 1993;11:1553–1558.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, O'Brien S, Kantarjian H, et al Fludarabine therapy in Waldenstrom's macroglobulinemia. Am J Med 1993;95:49–52.
   PubMed Web of Science ®Google Scholar
• Leblond V, Ben-Othman T, Deconinck E, et al Activity of fludarabine in previously treated Waldenstrom's macroglobulinemia: a report of 71 cases. Groupe Cooperatif Macroglobulinemie. J Clin Oncol 1998;16:2060–2064.
   PubMed Web of Science ®Google Scholar
• Dhodapkar MV, Jacobson JL, Gertz MA, Crowley JJ, Barlogie B. Prognostic factors and response to fludarabine therapy in Waldenstrom's macroglobulinemia: an update of a US intergroup trial (SW0G S9003). Semin Oncol 2003;30:220–225.
   PubMed Web of Science ®Google Scholar
• Weber DM, Dimopoulos MA, Delasalle K, Rankin K, Gavino M, Alexanian R. 2-Chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom's macroglobulinemia. Semin Oncol 2003;30:243–247.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Kantarjian H, Estey E, et al Treatment of Waldenstrom macroglobulinemia with 2-chlorodeoxyadenosine. Ann Intern Med 1993;118:195–198.
   PubMed Web of Science ®Google Scholar
• Gertz MA, Abonour R, Heffner LT, Greipp PR, Uno H, Rajkumar SV. Clinical value of minor responses after 4 doses of rituximab in Waldenstrom macroglobulinaemia: a follow-up of the Eastern Cooperative Oncology Group E3A98 trial. Br J Haematol 2009;147:677–680.
   PubMed Web of Science ®Google Scholar
• Gertz MA, Rue M, Blood E, Kaminer LS, Vesole DH, Greipp PR. Multicenter phase 2 trial of rituximab for Waldenstrom macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98). Leuk Lymphoma 2004;45:2047–2055.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Zervas C, Zomas A, et al Extended rituximab therapy for previously untreated patients with Waldenstrom's macroglobulinemia. Clin Lymphoma 2002;3:163–166.
   PubMedGoogle Scholar
• Treon SP, Emmanouilides C, Kimby E, et al Extended rituximab therapy in Waldenstrom's macroglobulinemia. Ann Oncol 2005;16:132–138.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, Castritis E, Bitsaktsis A, Pangalis GA. Treatment of relapsed or refractory Waldenstrom's macroglobulinemia with bortezomib. Haematologica 2005;90:1655–1658.
   PubMed Web of Science ®Google Scholar
• Chen CI, Kouroukis CT, White D, et al Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: A phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1570–1575.
   PubMed Web of Science ®Google Scholar
• Treon S, Hunter Z, Matous J, et al Phase II study of bortezomib in Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248. Blood 2005;106(Suppl. 1): (Abstract).
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Gertz M, Laplant B, et al Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia. J Clin Oncol 2010;28:1408–1414.
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Roccaro A, Hong F, et al Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia. Clin Cancer Res 2010;16:1033–1041.
   PubMed Web of Science ®Google Scholar
• Leblond V, Levy V, Maloisel F, et al Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenstrom macroglobulinemia in first relapse or with primary refractory disease. Blood 2001;98:2640–2644.
   PubMed Web of Science ®Google Scholar
• Treon SP, Ioakimidis L, Soumerai JD, et al Primary therapy of Waldenstrom macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG Clinical Trial 05-180. J Clin Oncol 2009;15:355–360.
   Google Scholar
• Treon SP, Soumerai JD, Branagan AR, et al Lenalidomide and rituximab in Waldenstrom's macroglobulinemia. Clin Cancer Res 2009;15:355–360.
   PubMed Web of Science ®Google Scholar
• Treon SP, Soumerai JD, Branagan AR, et al Thalidomide and rituximab in Waldenstrom macroglobulinemia. Blood 2008;112:4452–4457.
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Hong F, Padmanabhan S, et al Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. J Clin Oncol 2010;28:1422–1428.
   PubMed Web of Science ®Google Scholar
• Hunter Z, Boxer M, Kahl B, Patterson CJ, Soumerai JD, Treon SP. Phase II study of alemtuzumab in lymphoplasmacytic lymphoma: results of WMCTG trial 02-079. J Clin Oncol 2006;24(Suppl.): Abstract 427.
   Google Scholar
• Ghobrial I, Hong F, Padmanabhan S, et al Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenstrom's macroglobulinemia. Blood 2009;114(Suppl.): (Abstract 3752).
   PubMed Web of Science ®Google Scholar
• Weber D, Treon SP, Emmanouilides C, et al Uniform response criteria in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003;30:127–131.
   PubMed Web of Science ®Google Scholar
• Kimby E, Treon SP, Anagnostopoulos A, et al Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia. Clin Lymphoma Myeloma 2006;6:380–383.
   PubMedGoogle Scholar
• Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009;23:3–9.
   PubMed Web of Science ®Google Scholar
• Treon SP, Branagan AR, Ioakimidis L, et al Long term outcomes to fludarabine and rituximab in Waldenstrom macroglobulinemia. Blood 2008;113:3673–3678.
   PubMed Web of Science ®Google Scholar
• Leleu X, Moreau AS, Weller E, et al Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia. Leuk Lymphoma 2008;49:1104–1107.
   PubMed Web of Science ®Google Scholar
• Katzmann JA, Abraham RS, Dispenzieri A, Lust JA, Kyle RA. Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice. Clin Chem 2005;51:878–881.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Kantarjian H, Weber D, et al Primary therapy of Waldenstrom's macroglobulinemia with 2-chlorodeoxyadenosine. J Clin Oncol 1994;12:2694–2698.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Weber D, Delasalle KB, Keating M, Alexanian R. Treatment of Waldenstrom's macroglobulinemia resistant to standard therapy with 2-chlorodeoxyadenosine: identification of prognostic factors. Ann Oncol 1995;6:49–52.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Zervas C, Zomas A, et al Treatment of Waldenstrom's macroglobulinemia with rituximab. J Clin Oncol 2002;20:2327–2333.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Tsatalas C, Zomas A, et al Treatment of Waldenstrom's macroglobulinemia with single-agent thalidomide or with the combination of clarithromycin, thalidomide and dexamethasone. Semin Oncol 2003;30:265–269.
   PubMed Web of Science ®Google Scholar
• Rossi JF, Moreaux J, Hose D, et al Atacicept in relapsed/refractory multiple myeloma or active Waldenstrom's macroglobulinemia: a phase I study. Br J Cancer 2009;101:1051–1058.
   PubMed Web of Science ®Google Scholar
• Tam CS, Wolf MM, Westerman D, Januszewicz EH, Prince HM, Seymour JF. Fludarabine combination therapy is highly effective in first-line and salvage treatment of patients with Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma 2005;6:136–139.
   PubMedGoogle Scholar
• Leblond V, Tamburini J, Levy V, et al Treatment of Waldenström's macroglobulinemia with the combination of fludarabine and cyclophosphamide: results in 49 patients. Leukemia 2005;10:1831–1834.
   Google Scholar
• Dimopoulos MA, Hamilos G, Efstathiou E, et al Treatment of Waldenstrom's macroglobulinemia with the combination of fludarabine and cyclophosphamide. Leuk Lymphoma 2003;44:993–996.
   PubMed Web of Science ®Google Scholar
• Tam CS, Wolf M, Prince HM, et al Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma. Cancer 2006;106:2412–2420.
   PubMed Web of Science ®Google Scholar
• Hensel M, Villalobos M, Kornacker M, Krasniqi F, Ho AD. Pentostatin/cyclophosphamide with or without rituximab: an effective regimen for patients with Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma. Clin Lymphoma Myeloma 2005;6:131–135.
   PubMedGoogle Scholar
• Petrucci M, Avvisati G, Tribalto M, Giovangrossi P, Mandelli F. Waldenstrom's macroglobulinaemia: results of a combined oral treatment in 34 newly diagnosed patients. J Intern Med 1989;226:443–447.
   PubMed Web of Science ®Google Scholar
• Case DJ, Ervin TJ, Boyd MA, Redfield DL. Waldenstrom's macroglobulinemia: long-term results with the M-2 protocol. Cancer 1991;9:1–7.
   Web of Science ®Google Scholar
• Annibali O, Petrucci MT, Martini V, et al Treatment of 72 newly diagnosed Waldenstrom macroglobulinemia cases with oral melphalan, cyclophosphamide, and prednisone: results and cost analysis. Cancer 2005;103:582–587.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al Primary treatment of Waldenstrom macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol 2007;25:3344–3349.
   PubMed Web of Science ®Google Scholar
• Treon SP, Hunter Z, Barnagan AR. CHOP plus rituximab therapy in Waldenstrom's macroglobulinemia. Clin Lymphoma 2005;5:273–277.
   PubMedGoogle Scholar
• Buske C, Hoster E, Dreyling M, et al The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Leukemia 2009;23:153–161.
   PubMed Web of Science ®Google Scholar
• Treon SP, Soumerai JD, Branagan AR, et al Thalidomide and rituximab in Waldenstrom's macroglobulinemia. Blood 2008;15:355–360.
   Google Scholar
• Gertz MA, Geyer SM, Badros A, Kahl BS, Erlichman C. Early results of a phase I trial of oblimersen sodium for relapsed or refractory Waldenstrom's macroglobulinemia. Clin Lymphoma 2005;5:282–284.
   PubMedGoogle Scholar
• Patterson C, Soumerai J, Hunter Z, Leleu X, Ghobrial I, Treon SP. Sildenafil citrate suppresses disease progression in patients with Waldenstrom's macroglobulinemia. J Clin Oncol 2006;24(Suppl.): Abstract 435S.
   PubMed Web of Science ®Google Scholar
• Treon S, Jacob S, Patterson C, et al Imatinib mesylate (Gleevec) is active in relapsed/refractory Waldenstrom's macroglobulinemia: planned interim results of WMCTG Clinical Trial 05-140. Blood 2006;108(Suppl. 1): (Abstract 2484).
   PubMed Web of Science ®Google Scholar
• Ghobrial I, Harousseau JL, Treon SP, Wooldridge J, Leblond V. Enzastaurin in previously treated Waldenstrom's macroglobulinemia: an open-label, multicenter, phase II study. Blood 2009;114(Suppl. 1): (Abstract 3867).
   PubMed Web of Science ®Google Scholar
• O'Connor O, Stewart AK, Vallone M, et al A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of the Novel Proteasome Inhibitor Carfilzomib (PR-171) in Patients with Hematologic Malignancies. 2009;15:7085–7091.
   Google Scholar